ES2275416B1 - HALOGENATED DERIVATIVES OF 4H, 5H-TIENO (3,2-B: 4,5-B ') DIPIRROLES AND PROCEDURE AND CORRESPONDING UTILIZATIONS. - Google Patents

HALOGENATED DERIVATIVES OF 4H, 5H-TIENO (3,2-B: 4,5-B ') DIPIRROLES AND PROCEDURE AND CORRESPONDING UTILIZATIONS. Download PDF

Info

Publication number
ES2275416B1
ES2275416B1 ES200501764A ES200501764A ES2275416B1 ES 2275416 B1 ES2275416 B1 ES 2275416B1 ES 200501764 A ES200501764 A ES 200501764A ES 200501764 A ES200501764 A ES 200501764A ES 2275416 B1 ES2275416 B1 ES 2275416B1
Authority
ES
Spain
Prior art keywords
thieno
sem
dicarboxylate
dipyrrol
diethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200501764A
Other languages
Spanish (es)
Other versions
ES2275416A1 (en
Inventor
Ofir Arad Hadar
Jose Ignacio Borrell Bilbao
Jordi Morros Camps
Santiago Nonell Marrugat
Jordi Teixido Closa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Quimic de Sarria CETS Fundacio Privada
Original Assignee
Institut Quimic de Sarria CETS Fundacio Privada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Quimic de Sarria CETS Fundacio Privada filed Critical Institut Quimic de Sarria CETS Fundacio Privada
Priority to ES200501764A priority Critical patent/ES2275416B1/en
Publication of ES2275416A1 publication Critical patent/ES2275416A1/en
Application granted granted Critical
Publication of ES2275416B1 publication Critical patent/ES2275416B1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Derivados Halogenados de 4H,5H-tieno[3, 2-b:4,5-b'']dipirroles y procedimiento y utilizaciones correspondientes. La presente invención desarrolla la síntesis de sistemas 2,7-dihalo-4H,5H-tieno[3,2-b:4,5-b'']dipirroles de fórmula general (1), donde R puede ser alquilo (C1-5), bencilo o bencilo sustituido; G puede ser hidrógeno o trimetilsililetoximetil (SEM) y X puede ser cloro, bromo o iodo. Se describe el uso de los compuestos (1) como antecedentes de 2,2''-dipirroles 4,4''-diaril sustituidos y precursores de porficenos sustituidos en las posiciones 2,7,12,17 por grupos alquenilo, arilo o heteroarilo.Halogenated derivatives of 4H, 5H-thieno [3,2-b: 4,5-b ''] diproles and corresponding procedure and uses. The present invention develops the synthesis of systems 2,7-dihalo-4H, 5H-thieno [3,2-b: 4,5-b ''] dipyroles of general formula (1), where R can be (C1-) alkyl 5), benzyl or substituted benzyl; G can be hydrogen or trimethylsilylethoxymethyl (SEM) and X can be chlorine, bromine or iodine. The use of the compounds (1) is described as a background of 2,2 '' -4,4''-substituted diaryls and substituted precursors of positions 2,7,12,17 by alkenyl, aryl or heteroaryl groups .

Description

Derivados halogenados de 4H,5H-tieno[3,2-b:4,5-b']dipirroles y procedimiento y utilizaciones correspondientes.Halogenated derivatives of 4 H , 5 H -thieno [3,2- b : 4,5- b ' ] dipyroles and corresponding procedure and uses.

Campo de la invenciónField of the Invention

La presente invención se refiere a los derivados halogenados de 4H,5H-tieno[3,2-b:4,5-b']dipirroles de fórmula general 1, y a un procedimiento para su obtención.The present invention relates to the halogenated derivatives of 4 H , 5 H -thieno [3,2- b : 4,5- b ' ] dipyroles of general formula 1, and a process for obtaining them.

1one

donde R puede ser alquilo C_{1-5}, bencilo o bencilo sustituido, G puede ser hidrógeno o trimetilsililetoximetil (SEM) y X puede ser cloro, bromo o iodo.where R can be alkyl C 1-5, benzyl or substituted benzyl, G can be  hydrogen or trimethylsilylethoxymethyl (SEM) and X can be chlorine, bromine or iodine

Estado de la técnicaState of the art

Actualmente, en la lucha contra el cáncer se dispone, principalmente, de tres tipos de tratamientos: la cirugía, la radioterapia y la quimioterapia. A pesar de sus éxitos parciales presentan grandes inconvenientes como el trauma post-operatorio, la inmunodepresión o la toxicidad producida por la poca selectividad de los fármacos. Con el fin de mejorar y/o complementar dichas terapias convencionales, en los últimos años han surgido nuevas formas de tratamiento como la Terapia Fotodinámica del Cáncer (Photodynamic Therapy, PDT).Currently, in the fight against cancer, It has, mainly, three types of treatments: surgery, Radiation therapy and chemotherapy. Despite his partial successes they present great inconveniences like the trauma post-operative, immunosuppression or toxicity produced by the low selectivity of the drugs. With the purpose of improve and / or complement these conventional therapies, in the In recent years, new forms of treatment have emerged such as Photodynamic Therapy (PDT).

La PDT consiste en administrar por vía tópica o sistémica un fármaco fotosensibilizador, el cual una vez acumulado en el tejido neoplásico, debido a que los tumores tienen una mayor vascularización, pero un pobre drenaje linfático, se irradia con el haz de un láser. La acción de la luz sobre el fotosensibilizador produce el efecto fotodinámico, esto es, la generación de especies oxidantes tóxicas, principalmente oxígeno singlete, produciendo la apoptosis o la necrosis celular. Así pues, es una técnica doblemente selectiva. El efecto fotodinámico también se ha aplicado en dermatología, y en la inactivación de virus como el VIH y bacterias (G. Jori, D. Tonlorenzi, Int. Photodyn. 1999, 2(1), 2-3).PDT consists of administering a photosensitizing drug topically or systemically, which once accumulated in the neoplastic tissue, because the tumors have greater vascularization, but poor lymphatic drainage, is irradiated with a laser beam. The action of light on the photosensitizer produces the photodynamic effect, that is, the generation of toxic oxidizing species, mainly singlet oxygen, producing apoptosis or cell necrosis. Thus, it is a doubly selective technique. The photodynamic effect has also been applied in dermatology, and in the inactivation of viruses such as HIV and bacteria (G. Jori, D. Tonlorenzi, Int. Photodyn . 1999 , 2 (1), 2-3).

Actualmente, la terapia se aplica haciendo uso de un fotosensibilizador de origen natural llamado Photofrin® II. No obstante, presenta diversos inconvenientes. En primer lugar, el fármaco es, químicamente, una mezcla compleja de oligómeros de hematoporfirina lo cual provoca una baja reproducibilidad en los tratamientos. En segundo lugar, su máximo de absorción se halla muy por debajo del margen de longitudes de onda en el que la piel es transparente. Además presenta una gran fototoxicidad debido a la lentitud con la que se elimina del organismo. Estos hechos limitan la técnica.Currently, the therapy is applied using of a naturally occurring photosensitizer called Photofrin® II. However, it has several drawbacks. First, the drug is, chemically, a complex mixture of oligomers of hematoporphyrin which causes low reproducibility in the treatments Second, its maximum absorption is very high. below the wavelength range in which the skin is transparent. It also has a great phototoxicity due to the slowness with which it is eliminated from the organism. These facts limit The technique.

Así pues, un fotosensibilizador ideal debería poseer las siguientes características:So, an ideal photosensitizer should have the following characteristics:

\bullet?
Estabilidad química y fotoquímica.Chemical stability and photochemistry.

\bullet?
Estructura perfectamente determinada.Structure perfectly determined.

\bullet?
Coeficiente de absorción lo más elevado posible entre 650 y 800 nm.Absorption coefficient the most high possible between 650 and 800 nm.

\bullet?
Elevado rendimiento cuántico de triplete o de formación de especies activas de oxígeno.High quantum yield of triplet or formation of active oxygen species.

\bullet?
Localización en tumores.Location in tumors

\bullet?
Mínima toxicidad en ausencia de luz.Minimum toxicity in the absence of light.

\bullet?
Facilidad de eliminación del organismo.Ease of disposal of organism.

Con el fin de mejorar las propiedades del Photofrin® II han aparecido fotosensibilizadores de segunda generación. Entre estos cabe destacar las porfirinas, clorinas, bacterioclorinas, azaporfirinas, purpurinas, M(II)-texafirinas, ftalocianinas, naftalocianinas. y los porficenos (2).In order to improve the properties of the Photofrin® II have appeared second photosensitizers generation. These include porphyrins, chlorines, bacteriochlorines, azaporphyrins, glitter, M (II) -texaphyrins, phthalocyanines, naphthalocyanines and the porficenos (2).

22

En efecto, el porficeno (2, R^{1} = H), descubierto por E. Vogel en 1986 (E.Vogel, M. Köcher, H. Schmickler, J. Lex, Angew. Chem. Int. Ed. Engl. 1986, 25, 257-259), puede considerarse un isómero estructural de la porfirina el cual presenta un máximo de absorción a 630 nm (G. Jori, E. Vogel, A. D. Cross, Cytopharm, Inc., U.S. 4,913907).Indeed, the porficen (2, R1 = H), discovered by E. Vogel in 1986 (E.Vogel, M. Köcher, H. Schmickler, J. Lex, Angew. Chem. Int. Ed. Engl 1986 , 25 , 257-259), can be considered a structural isomer of porphyrin which has a maximum absorption at 630 nm (G. Jori, E. Vogel, AD Cross, Cytopharm, Inc., US 4,913907) .

El 2,7,12,17-tetrafenilporficeno (2, R^{1} = Ph) descrito por un grupo que comprende algunos de los inventores de la presente invención (S. Nonell, N. Bou, J. I. Borrell, J. Teixidó, A. Villanueva, A. Juarranz, M. Cañete, Tetrahedron Lett. 1995, 36, 3405-3408), presenta un desplazamiento batocrómico de 30 nm respecto al porficeno no substituido. Las propiedades fotofísicas del derivado G=Ph, y su complejo con paladio han sido estudiadas y lo convierten en un firme candidato para la terapia fotodinámica del cáncer (M. Cañete, M. Lapeña, A. Juarranz, V. Vendrell, J. I. Borrell, J. Teixidó, S. Nonell, A. Villanueva, Anti-Cancer Drug Design, 1997, 12, 543-554; M. Cañete, A. Ortiz, A. Juarranz, A. Villanueva, S. Nonell, J. I. Borrell, J. Teixidó, J. C. Stockert, Anti-cancer Drug Design, 2000, 15, 143-150).The 2,7,12,17-tetraphenylporphene (2, R1 = Ph) described by a group comprising some of the inventors of the present invention (S. Nonell, N. Bou, JI Borrell, J. Teixidó , A. Villanueva, A. Juarranz, M. Cañete, Tetrahedron Lett . 1995 , 36 , 3405-3408), presents a 30 nm batochromic displacement relative to the unsubstituted porcelain. The photophysical properties of the derivative G = Ph, and its complex with palladium have been studied and make it a strong candidate for photodynamic cancer therapy (M. Cañete, M. Lapeña, A. Juarranz, V. Vendrell, JI Borrell, J. Teixidó, S. Nonell, A. Villanueva, Anti-Cancer Drug Design , 1997 , 12 , 543-554; M. Cañete, A. Ortiz, A. Juarranz, A. Villanueva, S. Nonell, JI Borrell, J Teixidó, JC Stockert, Anti-cancer Drug Design , 2000 , 15 , 143-150).

No obstante, los porficenos se sintetizan mediante una síntesis lineal de ocho pasos que incorpora los substituyentes R^{1} desde el inicio. Este hecho dificulta, o incluso puede llegar a imposibilitar, la generación de derivados capaces de modelar las propiedades del fotosensibilizador.However, the porficenos are synthesized through an eight-step linear synthesis that incorporates the R 1 substituents from the beginning. This fact makes it difficult, or it can even make it impossible to generate derivatives able to model the properties of the photosensitizer.

Así pues, cabe considerar el diseño de fotosensibilizadores que por una parte posean un máximo de absorción desplazado hacia el rojo y que por otra parte, se obtengan por un itinerario sintético que permita un enfoque combinatorio con el fin de incorporar substituyentes para mejorar propiedades como la selectividad o la solubilidad.Thus, the design of photosensitizers that on the one hand have a maximum of absorption shifted towards red and that on the other hand, it get for a synthetic itinerary that allows a focus combinatorial in order to incorporate substituents to improve properties such as selectivity or solubility.

La posibilidad real de incorporar substituyentes muy diversos en esqueletos porficénicos amplía las posibilidades apuntadas en la literatura de usar los porficenos para otras aplicaciones, tanto biomédicas como industriales. Se podría citar como ejemplos las unidades de almacenamiento de información (TW552262, JP2002137547, JP2002114923), fotosensibilizadores para fotografía (US6372419, JP2001100353) o incluso sensores de oxígeno (JP2003344382).The real possibility of incorporating substituents very diverse in porficénicos skeletons expands the possibilities noted in the literature of using the porficenos for others applications, both biomedical and industrial. You could quote as examples the storage units (TW552262, JP2002137547, JP2002114923), photosensitizers for Photography (US6372419, JP2001100353) or even oxygen sensors (JP2003344382).

Desde el punto de vista sintético resulta atractiva una estrategia que permita introducir los substituyentes en las posiciones 4 y 4' de un sistema bipirrólico preformado. Para ello es necesario disponer de un bipirrol con halógenos en dichas posiciones. Actualmente existen muchas posibilidades sintéticas para funcionalizar heterociclos halogenados, entre las reacciones organometálicas destacan las catalizadas por Pd. La reacción de Suzuki por ejemplo permitiría introducir sustituyentes aromáticos en el heterociclo. Las posibilidades son muy diversas dado que existe una gran variedad de ácidos borónicos comerciales para realizar la reacción de Suzuki.From the synthetic point of view it turns out attractive a strategy that allows introducing substituents in positions 4 and 4 'of a preformed bipyrrolic system. For it is necessary to have a bipyrrole with halogens in these positions. There are currently many synthetic possibilities to functionalize halogenated heterocycles, between the reactions Organometallic ones stand out those catalyzed by Pd. The reaction of Suzuki for example would allow to introduce aromatic substituents in the heterocycle. The possibilities are very diverse since there is a wide variety of commercial boronic acids for Perform Suzuki's reaction.

En nuestro grupo ya se ha realizado la reacción de Suzuki sobre sistemas 2,2'-biimidazólicos como estrategia para obtener azaporficenos (S. Nonell, J. I. Borrell, S. Borrós, C. Colominas, O. Rey, N. Rubio, D. Sánchez, J. Teixidó, Eur. J. Org. Chem., 2003, 1635-1640); la presente invención utiliza los tienodipirroles halogenados 1 como antecedentes de 2,2'-bipirroles 4,4'-diaril sustituidos susceptibles de ser transformados en porficenos 2 mediante reacciones químicas previamente descritas por nuestro equipo (A. Gavaldá, J. I. Borrell, J. Teixidó, S. Nonell, O. Arad, R. Grau, M. Cañete, A. Juarranz, A. Villanueva, J. C. Stockert, J. Porphyrins Phthalocyanines, 2001, 5, 846-852).In our group, Suzuki's reaction to 2,2'-biimidazole systems has already been carried out as a strategy to obtain azaporficenos (S. Nonell, JI Borrell, S. Borrós, C. Colominas, O. Rey, N. Rubio, D. Sánchez, J. Teixidó, Eur. J. Org. Chem ., 2003 , 1635-1640); The present invention uses halogenated thienodiproles 1 as a background of substituted 2,2'-biproles 4,4'-diaryl capable of being transformed into porficenos 2 by chemical reactions previously described by our team (A. Gavaldá, JI Borrell, J. Teixidó , S. Nonell, O. Arad, R. Grau, M. Cañete, A. Juarranz, A. Villanueva, JC Stockert, J. Porphyrins Phthalocyanines , 2001 , 5 , 846-852).

Objeto de la invenciónObject of the invention

Los autores de la presente invención han diseñado un procedimiento o itinerario nuevo que permite la obtención de los nuevos tienodipirroles halogenados 1 a partir de 4H,5H-tieno[3,2-b:4,5-b]dipirrol-3,6-dicarboxilatos de di(R) (3), donde R puede ser alquilo C_{1-5}, bencilo o bencilo sustituido.The authors of the present invention have designed a new procedure or itinerary that allows the obtaining of the new halogenated thipedipers 1 from 4 H , 5 H -thieno [3,2- b : 4,5- b ] dipyrrol-3, Di (R) 6-dicarboxylates (3), where R can be C 1-5 alkyl, benzyl or substituted benzyl.

       \vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
    

33

La invención tiene asimismo por objeto la utilización preferente de dichos compuestos 1 como antecedentes de 2,2'-dipirroles 4,4'-diaril sustituidos como precursores de porficenos 2 sustituidos en las posiciones 2,7,12,17 por grupos alquenilo, arito o heteroarilo.The object of the invention is also the preferred use of said compounds 1 as a background of 2,2'-dipyroles 4,4'-diaryl substituted as precursors of porficenos 2 substituted in the positions 2,7,12,17 by alkenyl, arite or heteroaryl groups.

Descripción detallada de una forma de realización de la invenciónDetailed description of an embodiment of the invention

El procedimiento de obtención de los tienodipirroles 1 se inicia con la obtención de los 4H,5H-tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilatos de di(R) (3) mediante el procedimiento descrito en 1976 por Farnier et al. para la síntesis del 4H,5H-tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo (3, R = Et) (M. Farnier, S. Soth, P. Fournari, Can. J. Chem. 1976, 54, 1074-1082). Así, se trata el comercialmente asequible tiofeno-2,5-dicarboxaldehido (4) con el correspondiente azidoacetato de (R) (5), donde R es alquilo C_{1-5}, bencilo o bencilo sustituido, en presencia del alcohol ROH y sodio molecular para rendir 2,5-bis(2-azido-2-(R)oxicarbonilvinil)tiofeno (6), donde R es alquilo C_{1-5}, bencilo o bencilo sustituido. Los compuestos 6 se transforman en el correspondiente 4H,5H-tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de di(R) (3) por calefacción en xileno. El diéster 3 es el intermedio común a partir del cual se obtienen los tienodipirroles halogenados 1. El grupo R es preferentemente el grupo etilo.The procedure for obtaining thienodiproles 1 begins with the obtaining of 4 H , 5 H -thieno [3,2- b : 4,5- b ' ] dipyrrol-3,6-dicarboxylates of di (R) (3 ) by the procedure described in 1976 by Farnier et al . for the synthesis of 4 H , 5 H -thieno [3,2- b : 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate (3, R = Et) (M. Farnier, S. Soth, P. Fournari, Can. J. Chem . 1976 , 54 , 1074-1082). Thus, the commercially available thiophene-2,5-dicarboxaldehyde (4) is treated with the corresponding azidoacetate of (R) (5), where R is C 1-5 alkyl, benzyl or substituted benzyl, in the presence of ROH alcohol and molecular sodium to yield 2,5-bis (2-azido-2- (R) oxycarbonylvinyl) thiophene (6), where R is C 1-5 alkyl, benzyl or substituted benzyl. Compounds 6 are transformed into the corresponding 4 H , 5 H -thieno [3,2- b : 4,5- b ' ] di (R) dipyrrol-3,6-dicarboxylate (3) by heating in xylene. The diester 3 is the common intermediate from which halogenated thienodiproles 1 are obtained. The R group is preferably the ethyl group.

44

       \vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
    

El procedimiento de obtención de los compuestos 1 (R = Et) se inicia con la halogenación del tienodipirrol 3 (R = Et). Las dificultades encontradas para bromar 3 (R = Et) con diversos agentes bromantes tradicionales en la química de pirroles tales como la N-bromosuccinimida, la 1,3-dibromo-5,5-dimetilhidantoína, etc en un gran número de disolventes, llevaron a los inventores de la presente invención a ensayar el bromo elemental como agente bromante pese a no ser utilizado habitualmente en pirroles.The process for obtaining compounds 1 (R = Et) begins with the halogenation of thienodipyrrole 3 (R = Et). The difficulties encountered in brominating 3 (R = Et) with various traditional brominating agents in the chemistry of pyrroles such as N- bromosuccinimide, 1,3-dibromo-5,5-dimethylhydantoin, etc. in a large number of solvents, led to the inventors of the present invention to test elemental bromine as a brominating agent even though it is not commonly used in pyrroles.

Sorprendentemente al tratar con bromo el tienodipirrol 3 (R = Et) utilizando una mezcla 5:2 de acetato de etilo y ácido acético como disolvente se obtiene por precipitación el dibromotienodipirrol 1 (R = Et, X = Br, G = H) con un rendimiento del 90%. Dicha precipitación no se da con el derivado diiodado, en principio más reactivo que el bromado para una posterior reacción de Suzuki, lo que hace necesario el empleo de cromatografía de columna para su aislamiento. Por su parte, el derivado diclorado, obtenible por tratamiento con Cl_{2}, es de menor interés al ser menos reactivo que el dibromado en condiciones de Suzuki. Todo ello hace que el derivado dibromado 1 (R = Et, X = Br, G = H) sea el compuesto idóneo para manipulaciones sintéticas posteriores.Surprisingly when dealing with bromine the thienodipyrrole 3 (R = Et) using a 5: 2 mixture of acetate ethyl and acetic acid as solvent is obtained by precipitation dibromothienodipyrrole 1 (R = Et, X = Br, G = H) with a yield of 90%. Such precipitation does not occur with the diiodinated derivative, in principle more reactive than brominated for a subsequent reaction of  Suzuki, which makes the use of column chromatography necessary For your isolation. On the other hand, the dichlorinated derivative, obtainable by treatment with Cl 2, it is of less interest because it is less reagent than dibromado in Suzuki conditions. All this does that the dibromated derivative 1 (R = Et, X = Br, G = H) be the compound suitable for subsequent synthetic manipulations.

55

Se han hecho numerosas pruebas con el tienodipirrol dibromado 1 (R = Et, X = Br, G = H) y se ha llegado a la conclusión que esta molécula no da la reacción de Suzuki con buenos rendimientos. En la bibliografía aparecen ejemplos de Suzuki en pirroles donde este problema se soluciona protegiendo los nitrógenos del heterociclo (Handy et.al., Tetrahedron. Lett. 2003, 44, 427-430, Ghosez et.al., Can. J. Chem. 2001, 79, 1827-1839). Teniendo en cuenta estos precedentes se ensayó la protección de los nitrógenos del tienodipirrol bromado 1 (R = Et, X = Br, G = H).Numerous tests have been done with dibrominated thienodipyrrole 1 (R = Et, X = Br, G = H) and it has been concluded that this molecule does not give Suzuki reaction with good yields. Examples of Suzuki in pyroles appear in the literature where this problem is solved by protecting the nitrogens of the heterocycle (Handy et.al., Tetrahedron. Lett . 2003 , 44 , 427-430, Ghosez et.al. , Can. J. Chem . 2001 , 79 , 1827-1839). Taking into account these precedents, the protection of the brominated thienodipyrrole 1 nitrogens was tested (R = Et, X = Br, G = H).

La protección con cloroformiato de metilo en presencia de ioduro de tetrabutilamonio y carbonato sódico conduce a la metilación de los nitrógenos. Dado que el grupo metilo es un grupo protector muy difícil de eliminar, ésta no es una buena aproximación. Se intentó la protección con cloroformiato de metilo mediante la ionización previa con hidruro sódico pero sólo se consiguió proteger uno de los nitrógenos, lo cual es insuficiente para poder realizar la reacción de Suzuki.Protection with methyl chloroformate in presence of tetrabutylammonium iodide and sodium carbonate leads to the methylation of nitrogen. Since the methyl group is a protective group very difficult to eliminate, this is not a good approach. Protection with methyl chloroformate was attempted by prior ionization with sodium hydride but only managed to protect one of the nitrogen, which is insufficient to be able to carry out the Suzuki reaction.

Finalmente, se ha conseguido la protección simultánea de los dos nitrógenos de 1 (R = Et, X = Br, G = H) mediante el grupo protector trimetilsililetoximetil (abreviado como SEM) por tratamiento con cloruro de trimetililsililetoximetilo (SEM-Cl) en THF utilizando NaH como base para rendir el 2,7-dibromo-4H,5H-bis(trimetilsililetoximetil)tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo 1 (R = Et, X = Br, G = SEM).Finally, simultaneous protection of the two nitrogens of 1 (R = Et, X = Br, G = H) has been achieved by the trimethylsilylethoxymethyl protecting group (abbreviated as SEM) by treatment with trimethylsilylethyloxymethyl chloride (SEM-Cl) in THF using NaH as a base to yield 2,7-dibromo-4 H , 5 H- bis (trimethylsilylethoxymethyl) thieno [3,2- b : 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate 1 (R = Et, X = Br, G = SEM).

El SEM, aunque voluminoso, permite la doble protección,a diferencia de otros grupos protectores voluminosos pero de estructura no lineal. Esta doble protección se ha de realizar a temperatura ambiente porque si se hace a baja temperatura solamente se obtiene el término de monoprotección 7. Además el SEM es muy estable en una gran variedad de condiciones lo que permite la posterior utilización de dicha molécula en reacciones de sustitución del halógeno por otros restos. Otra ventaja que presenta este grupo protector es la de dar solubilidad al tienodipirrol en numerosos disolventes orgánicos, entre ellos el hexano, lo que permite su aplicación en numerosas reacciones que se dan en medio apolar.The SEM, although bulky, allows double protection, unlike other bulky protective groups but of nonlinear structure. This double protection must be perform at room temperature because if done at low temperature only the term of protection 7 is obtained. In addition, the SEM is very stable in a wide variety of conditions. which allows the subsequent use of said molecule in Halogen substitution reactions with other residues. Other advantage of this protective group is to give solubility thienodipyrrole in numerous organic solvents, including the hexane, which allows its application in numerous reactions that they give in the middle apolar.

66

Se ha comprobado que es posible sustituir los dos halógenos de los tienodipirroles halogenados 1, cuyos nitrógenos anulares estén protegidos con el grupo SEM, por restos alquenilo, arilo o heteroarílo mediante la reacción de Suzuki en condiciones similares a las previamente descritas por nuestro grupo para obtener azaporficenos (S. Nonell, J. I. Borrell, S. Borrós, C. Colominas, O. Rey, N. Rubio, D. Sánchez, J. Teixidó, Eur. J. Org. Chem., 2003, 1635-1640), Así, el 2,7-dibromo-4H,5H-bis(trimetilsililetoximetil)tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo 1 (R = Et, X = Br, G = SEM) sufre reacción de Suzuki en dioxano y en presencia de un catalizador de paladio, tal como el complejo tetrakis(trifenilfosfina) paladio (0), y de una base, tal como carbonato sódico o fluoruro de cesio, con un derivado borónico 8, donde R_{2} puede ser hidrógeno (ácido borónico) o ambos R_{2} formar parte de una misma cadena hidrocarbonada (éster borónico del propilenglicol o del pinacol) y R_{1} puede ser un grupo alquenilo (vinilo o estirilo), o un grupo arilo el cual puede estar no sustituido o sustituido por uno o varios grupos alquilo C_{1-6}, alcoxilo C_{1-6}, hidroxi, amino, mono- o dialquilamino o hidroxicarbonilo, o un grupo heteroarilo el cual puede estar no sustituido o sustituido por uno o más grupos alquilo C_{1-6} para rendir el correspondiente sistema disustiuido 9.It has been found that it is possible to replace the two halogens of halogenated thienodiproles 1, whose annular nitrogens are protected with the SEM group, by alkenyl, aryl or heteroaryl moieties by Suzuki reaction under conditions similar to those previously described by our group to obtain azaporficenos (S. Nonell, JI Borrell, S. Borrós, C. Colominas, O. Rey, N. Rubio, D. Sánchez, J. Teixidó, Eur. J. Org. Chem ., 2003 , 1635-1640), So , 2,7-dibromo-4 H , 5 H -bis (trimethylsilylethoxymethyl) thieno [3,2- b : 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate 1 (R = Et, X = Br, G = SEM) undergoes Suzuki reaction in dioxane and in the presence of a palladium catalyst, such as the tetrakis (triphenylphosphine) palladium (0) complex, and of a base, such as sodium carbonate or cesium fluoride, with a boronic derivative 8, where R2 can be hydrogen (boronic acid) or both R2 form part of the same hydrocarbon chain (boronic ester of propylene glycol that of pinacol) and R 1 may be an alkenyl group (vinyl or styryl), or an aryl group which may be unsubstituted or substituted by one or more C 1-6 alkyl, C 1- alkoxy groups 6}, hydroxy, amino, mono- or dialkylamino or hydroxycarbonyl, or a heteroaryl group which may be unsubstituted or substituted by one or more C 1-6 alkyl groups to yield the corresponding disubstituted system 9.

77

Los sistemas 9 pueden ser transformados en 5,5'-diformil-2,2'-bipirroles.4,4'-di(R^{1}) sustituidos 10 (donde R^{1} puede ser alquenilo, arilo o heteroarilo según la definición anterior), precursores inmediatos de porficenos 2,7,12,17-tetrasustituidos 2, por desulfurización según el método descrito por Farnier et al. (M. Farnier, S. Soth, P. Fournari, Can. J. Chem. 1976, 54, 1074-1082), seguido de eliminación del grupo protector SEM según el método descrito por Delgado (A. Delgado, J. Clardy, J. Org. Chem. 1993, 58, 2862-2866) y posterior transformación de los grupos éster en aldehído según el método previamente descrito por nuestro grupo (A. Gavaldá, J. I. Borrell, J. Teixidó, S. Nonell, O. Arad, R. Grau, M. Cañete, A. Juarranz, A. Villanueva, J. C. Stockert, J. Porphyrins Phthalocyanines, 2001, 5, 846-852).The systems 9 can be transformed into substituted 5,5'-diformyl-2,2'-biproles.4,4'-di (R1) (where R1 can be alkenyl, aryl or heteroaryl according to the previous definition), immediate precursors of 2,7,12,17-tetrasubstituted porphors 2, by desulfurization according to the method described by Farnier et al . (M. Farnier, S. Soth, P. Fournari, Can. J. Chem . 1976 , 54 , 1074-1082), followed by removal of the SEM protecting group according to the method described by Delgado (A. Delgado, J. Clardy, J. Org. Chem . 1993 , 58 , 2862-2866) and subsequent transformation of the ester groups into aldehyde according to the method previously described by our group (A. Gavaldá, JI Borrell, J. Teixidó, S. Nonell, O. Arad , R. Grau, M. Cañete, A. Juarranz, A. Villanueva, JC Stockert, J. Porphyrins Phthalocyanines , 2001 , 5 , 846-852).

88

Además, los 2,2'-bipirroles 10 son intermedios en la síntesis de numerosos fotosensibilizadores a parte de los porficenos (corroles, safirinas, rosarinas, rubirinas,...). Por lo tanto se puede extender la aplicación de los tienodipirroles 1 a la síntesis de otros fotosensibilizadores.In addition, the 2,2'-bipirroles 10 they are intermediate in the synthesis of numerous photosensitizers to part of the porficenos (corroles, safirinas, rosarinas, rubirinas, ...). Therefore the application of the Tienodiproles 1 to the synthesis of other photosensitizers.

A continuación, para una mejor comprensión de la presente invención, sin que deba ser interpretado como limitaciones a la misma, se exponen los siguientesNext, for a better understanding of the present invention, without it being construed as limitations to it, the following are exposed

Ejemplos Examples Ejemplo 1Example 1 Obtención del 2,7-dibromo-4H,5H-tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo 1 (R = Et, X = Br, G = H)Obtaining 2,7-dibromo-4 H , 5 H -thieno [3,2- b : 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate 1 (R = Et, X = Br, G = H)

Se añade una disolución de 3 mL de Br_{2} en 45 mL de AcOH sobre una suspensión de 3,0 g (9,7 mmol) del tienodipirrol 3 (R = Et) en una mezcla de 250 mL de AcOEt y 100 mL de AcOH. A continuación se agita durante ocho horas a temperatura ambiente. El precipitado resultante se filtra, se lava con 3x50 mL de solución acuosa de NaHCO_{3} y, finalmente, se seca en desecador de vacío a 50ºC sobre pentóxido de fósforo. Se obtienen 4,1 g (8,7 mmol, 89%) de 1 (R = Et, X = Br, G = H) como un sólido blanco, p. fus. > 290 (d). IR (KBr) \nu (cm^{-1}): 3417, 3327, 2924, 2853, 1686, 1649, 1375, 1230; ^{1}H-RMN (DMSO-d_{6}, 300 MHz) \delta (ppm): 11.52 (s, 2H, NH), 4.34 (q, 4H, J=7.2Hz, O-CH_{2}CH_{3}), 1.35 (t, 6H, J=7.2Hz, O-CH_{2}CH_{3}); ^{13}C-RMN (DMSO-d_{6}, 75.5 MHz) \delta (ppm): 158.9, 127.7, 125.2, 121.9, 96,1, 60,6, 14.3; MS (70 eV): m/z = 463.6 ([M+2H]^{+}), 419.6, 371.6, 264.7; HRMS (High Resolution Mass Spectrometry - Espectrometría de Masas de Alta Resolución): C_{14}H_{12}Br_{2}N_{2}O_{4}S, calculado: 461.8884, obtenido: 461.8892; Análisis Elemental (AE) Calculado para C_{14}H_{12}Br_{2}N_{2}O_{4}S: C, 36.23; H, 2.61; N, 6.04; S, 6.91. Obtenido: C, 36.11; H, 2.54; N, 5.98; S, 6.59.A solution of 3 mL of Br 2 in 45 mL of AcOH is added on a suspension of 3.0 g (9.7 mmol) of thienodipyrrole 3 (R = Et) in a mixture of 250 mL of AcOEt and 100 mL of AcOH. It is then stirred for eight hours at room temperature. The resulting precipitate is filtered, washed with 3x50 mL of aqueous NaHCO3 solution and, finally, dried in a vacuum desiccator at 50 ° C over phosphorus pentoxide. 4.1 g (8.7 mmol, 89%) of 1 (R = Et, X = Br, G = H) are obtained as a white solid, e.g. fus. > 290 (d). IR (KBr) ν (cm -1): 3417, 3327, 2924, 2853, 1686, 1649, 1375, 1230; 1 H-NMR (DMSO-d 6, 300 MHz) δ (ppm): 11.52 (s, 2H, NH), 4.34 (q, 4H, J = 7.2Hz, OC H 2 CH 3), 1.35 (t, 6H, J = 7.2Hz, O-CH 2 C H 3); 13 C-NMR (DMSO-d 6, 75.5 MHz) δ (ppm): 158.9, 127.7, 125.2, 121.9, 96.1, 60.6, 14.3; MS (70 eV): m / z = 463.6 ([M + 2H] +), 419.6, 371.6, 264.7; HRMS (High Resolution Mass Spectrometry - High Resolution Mass Spectrometry): C_ {14} H_ {12} Br_ {N} {2} O4 {S}, calculated: 461.8884, obtained: 461.8892; Elemental Analysis (EA) Calculated for C 14 H 12 Br 2 N 2 O 4 S: C, 36.23; H, 2.61; N, 6.04; S, 6.91. Obtained: C, 36.11; H, 2.54; N, 5.98; S, 6.59.

Ejemplo 2Example 2 Obtención de 2,7-dibromo-4H,5H-bis(trimetilsililetoximetil)tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo 1 (R = Et, X = Br, G = SEM)Obtaining 2,7-dibromo-4 H , 5 H -bis (trimethylsilylethoxymethyl) thieno [3,2- b : 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate 1 (R = Et, X = Br, G = SEM)

Se hace una suspensión de 11 g (24 mmol) del dibromotienobipirrol 1 (R = Et, X = Br, G = H) en 50 mL de THF anhidro bajo atmósfera de argón. A continuación se añade, en pequeñas porciones, 2.1 g (0.52 mol) de NaH al 60% en parafina. La mezcla resultante se deja en agitación durante 15 min a temperatura ambiente. Se adicionan lentamente 15 mL (80 mmol) de cloruro de trimetilsililetoximetilo (SEM-Cl) y se deja agitando durante 1 hora a temperatura ambiente. Se adicionan 100 g de hielo y se agita hasta la aparición de un precipitado. El precipitado resultante se filtra, se lava con MeOH hasta que el sólido quede blanco y se seca en un desecador de vacío a 50ºC sobre pentóxido de fósforo obteniéndose 13.4 g (18 mmol, 77%) de 1 (R = Et, X = Br, G = SEM). Las aguas madres se extraen con hexano, se secan sobre MgSO_{4}, y se elimina el disolvente a vacío recuperándose 3.0 g (4 mmol, 17%) más de 1 (R = Et, X = Br, G = SEM), p. fus. 127-129ºC. IR (KBr) \nu (cm^{-1}): 2952, 2902, 1705, 1382, 1319, 1228, 1088, 920, 859, 835; ^{1}H-RMN (CDCl_{3}, 300 MHz) \delta (ppm): 6.27 (s, 4H, N-CH_{2}), 4.41 (q, 4H, J=7.2Hz, O-CH_{2}CH_{3}), 3.51 (t, 4H, J=8.4Hz, O-CH_{2}), 1.45(t, 6H, J=7.2Hz, O-CH_{2}CH_{3}); 0.83 (t, 4H, J=8.4 Hz, Si-CH_{2}), -0.07 (s, 18H, Si-(CH_{3})_{3}); ^{13}C-RMN (CDCl_{3}, 75.5 MHz) \delta (ppm): 160.5, 130.7, 128.5, 123.9, 99.6, 75.0, 65.9, 61.1, 17.9, 14.4, -1.4; MS (ESI-TOF): m/z = 747.0 ([M+Na+2H]^{+}), 337.3, 236.1, 218.2, 163.0. HRMS (MALDI-TOF): C_{26}H_{40}Br_{2}N_{2}O_{6}SSi_{2}+Na, Calculado: 745.041; obtenido 745.040; AE: Calculado para C_{26}H_{40}Br_{2}N_{2}O_{6}SSi_{2}: C, 43.09; H, 5.56; N, 3.87; S, 4.42. Obtenido: C, 43.25; H, 5.37; N, 3.64; S, 4.21.A suspension of 11 g (24 mmol) of dibromothienobipyrrole 1 (R = Et, X = Br, G = H) is made in 50 mL of anhydrous THF under an argon atmosphere. Then, in small portions, 2.1 g (0.52 mol) of 60% NaH in paraffin is added. The resulting mixture is allowed to stir for 15 min at room temperature. 15 mL (80 mmol) of trimethylsilylethoxymethyl chloride (SEM-Cl) are added slowly and allowed to stir for 1 hour at room temperature. 100 g of ice are added and stirred until a precipitate appears. The resulting precipitate is filtered, washed with MeOH until the solid is white and dried in a vacuum desiccator at 50 ° C on phosphorus pentoxide to obtain 13.4 g (18 mmol, 77%) of 1 (R = Et, X = Br , G = SEM). The mother liquors are extracted with hexane, dried over MgSO4, and the solvent is removed in vacuo recovering 3.0 g (4 mmol, 17%) more than 1 (R = Et, X = Br, G = SEM), p. fus. 127-129 ° C. IR (KBr) ν (cm -1): 2952, 2902, 1705, 1382, 1319, 1228, 1088, 920, 859, 835; 1 H-NMR (CDCl 3, 300 MHz) δ (ppm): 6.27 (s, 4H, N-CH 2), 4.41 (q, 4H, J = 7.2Hz, OC H _ {2} {3} CH), 3.51 (t, 4H, J = 8.4Hz, O-CH {2}), 1.45 (t, 6H, J = 7.2Hz, O-CH {2} {3 C H }); 0.83 (t, 4H, J = 8.4 Hz, Si-CH 2), -0.07 (s, 18H, Si- (CH 3) 3); 13 C-NMR (CDCl 3, 75.5 MHz) δ (ppm): 160.5, 130.7, 128.5, 123.9, 99.6, 75.0, 65.9, 61.1, 17.9, 14.4, -1.4; MS (ESI-TOF): m / z = 747.0 ([M + Na + 2H] +), 337.3, 236.1, 218.2, 163.0. HRMS (MALDI-TOF): C 26 H 40 Br 2 N 2 O 6 SSi 2 + Na, Calculated: 745.041; obtained 745,040; AE: Calculated for C 26 H 40 Br 2 N 2 O 6 SSi 2: C, 43.09; H, 5.56; N, 3.87; S, 4.42. Obtained: C, 43.25; H, 5.37; N, 3.64; S, 4.21.

Ejemplo 3Example 3 Obtención de 2,7-difenil-4H,5H-bis(trimetilsililetoximetil)tieno[3,2-b,4,5-b']dipirrol-3,6-dicarboxilato de dietilo 9 (R^{1} = Ph)Obtaining 2,7-diphenyl-4 H , 5 H -bis (trimethylsilylethoxymethyl) thieno [3,2- b , 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate 9 (R1 = Ph)

Se disuelven 100 mg (138 \mumol) del 2,7-dibromo-4H,5H-di(trimetilsililetoximetil)tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo 1 (R = Et, X = Br, G = SEM), 50 mg (410 \mumol) de ácido fenilborónico 8 (R^{1} = Ph, R_{2} = H) en 60 mL de 1,4-dioxano. A continuación, se añade una disolución acuosa saturada de 57 mg (412 \mumol) de carbonato potásico en 1 mL de agua y se desoxigena toda la mezcla con N_{2} durante media hora. Finalmente se añaden 25 mg (22 \mumol) de tetrakis(trifenilfosfina) de paladio (0) y la mezcla se lleva a reflujo, bajo atmósfera de argón, durante 16 horas. La solución resultante se deja enfriar, se añaden 30 mL de agua y se extrae con 3x50 mL de hexano.100 mg (138 µmol) of 2,7-dibromo-4 H , 5 H -di (trimethylsilylethoxymethyl) thieno [3,2- b : 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate are dissolved 1 (R = Et, X = Br, G = SEM), 50 mg (410 µm) of phenylboronic acid 8 (R 1 = Ph, R 2 = H) in 60 mL of 1.4- dioxane Next, a saturated aqueous solution of 57 mg (412 µm) of potassium carbonate in 1 mL of water is added and the entire mixture is deoxygenated with N2 for half an hour. Finally, 25 mg (22 µm) of palladium tetrakis (triphenylphosphine) (0) are added and the mixture is refluxed under an argon atmosphere for 16 hours. The resulting solution is allowed to cool, 30 mL of water are added and extracted with 3x50 mL of hexane.

Los extractos orgánicos se secan sobre MgSO_{4}, se elimina el disolvente a vacio y el residuo se cromatografía usando una mezcla 1:2 de acetato de etilo/hexano como eluyente. Se obtienen 76 mg (106 \mumol, 77%) de 9 (R^{1} = Ph) como un sólido blanco, p. fus. 90-92ºC. IR (KBr) \nu (cm^{-1}): 3061, 3029, 2980, 2953, 2897, 1948, 1882, 1698 1397, 1382, 1317, 1249, 1238, 1179, 1101, 1078, 860, 836, 699; ^{1}H-RMN (CDCl_{3}, 300 MHz) \delta (ppm): 7.5-7.3 (m, 10H, Ph), 6.33 (s, 4H, N-CH_{2}), 4,14 (q, 4H, J=6.9Hz, O-CH_{2}CH_{3}), 3.61 (t, 4, J=8.4Hz, O-CH_{2}), 1.05 (t, 2H, J=6.9Hz, O-CH_{2}CH_{3}), 0.91 (t, 4H, J=8.4 Hz, Si-CH_{2}), -0.04 (s, 18H, Si-(CH_{3})_{3}); ^{13}C-RMN (CDCl_{3}, 75.5 MHz) \delta (ppm): 161.8, 134.5, 129.9, 129.2, 128.7, 127.8, 127.2, 126.8, 122.5, 74.6, 65.7, 60.5, 18.0, 13.8, -1.3. MS (ESI-TOF): m/z = 741.5 ([M+Na]^{+}), 601.4, 416.5, 368.5, 288.4.The organic extracts are dried over MgSO4, the solvent is removed in vacuo and the residue is chromatographed using a 1: 2 mixture of ethyl acetate / hexane as eluent. 76 mg (106 µmol, 77%) of 9 (R1 = Ph) are obtained as a white solid, e.g. fus. 90-92 ° C. IR (KBr) ν (cm -1): 3061, 3029, 2980, 2953, 2897, 1948, 1882, 1698 1397, 1382, 1317, 1249, 1238, 1179, 1101, 1078, 860, 836, 699; 1 H-NMR (CDCl 3, 300 MHz) δ (ppm): 7.5-7.3 (m, 10H, Ph), 6.33 (s, 4H, N-CH 2), 4.14 (q, 4H, J = 6.9Hz, OC H 2 CH 3), 3.61 (t, 4, J = 8.4Hz, O-CH 2), 1.05 (t, 2H, J = 6.9 Hz, O-CH 2 C H 3), 0.91 (t, 4H, J = 8.4 Hz, Si-CH 2), -0.04 (s, 18H, Si- (CH 3) _{3}); 13 C-NMR (CDCl 3, 75.5 MHz) δ (ppm): 161.8, 134.5, 129.9, 129.2, 128.7, 127.8, 127.2, 126.8, 122.5, 74.6, 65.7, 60.5, 18.0, 13.8, -1.3. MS (ESI-TOF): m / z = 741.5 ([M + Na] +), 601.4, 416.5, 368.5, 288.4.

Claims (8)

1. Compuesto de fórmula 1, donde R puede ser alquilo C_{1-5}, bencilo o bencilo sustituido, G puede ser hidrógeno o trimetilsililetoximetil (SEM) y X puede ser cloro, bromo o iodo:1. Compound of formula 1, where R can be C 1-5 alkyl, benzyl or substituted benzyl, G it can be hydrogen or trimethylsilylethoxymethyl (SEM) and X can be chlorine, bromine or iodine: 99 2. Compuesto según la reivindicación 1, caracterizado porque G = SEM, R= Et y X = Br.2. Compound according to claim 1, characterized in that G = SEM, R = Et and X = Br. 1010 3. Compuesto según la reivindicación 1, caracterizado porque G = H, R = Et y X = Br.3. Compound according to claim 1, characterized in that G = H, R = Et and X = Br. 11eleven 4. Un procedimiento para la preparación de un compuesto de fórmula 1 según por lo menos una de las reivindicaciones 1 a 3 caracterizado porque comprende las siguientes etapas:4. A process for the preparation of a compound of formula 1 according to at least one of claims 1 to 3 characterized in that it comprises the following steps:
(a)(to)
Halogenar 4H,5H-tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de di(R) (3), para rendir el 2,7-dihalo-4H, 5H-tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de di(R) (1) (G = H).Halogenar 4 H , 5 H -thieno [3,2- b : 4,5- b ' ] di (R) dipyrrol-3,6-dicarboxylate (3), to yield 2,7-dihalo-4 H , 5 H -thieno [3,2- b : 4,5- b ' ] di (R) dipyrrol-3,6-dicarboxylate (1) (G = H).
1212
(b)(b)
Opcionalmente, proteger los nitrógenos del tienodipirrol 2,7-dihalo sustituido 1 (G = H) con cloruro de trimetilsililetoximetil para obtener el 2,7-dihalo-4H,5H-bis(trimetilsililetoximetil)tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de di(R) (1) (G = SEM).Optionally, protect the nitrogens of thienodipyrrole 2,7-dihalo substituted 1 (G = H) with trimethylsilylethoxymethyl chloride to obtain 2,7-dihalo-4 H , 5 H -bis (trimethylsilylethoxymethyl) thieno [3,2- b : 4,5- b '] dipyrrole-3,6-dicarboxylate di (R) (1) (G = SEM).
1313
5. Un procedimiento para la preparación de un compuesto de fórmula 1 (R = Et, X = Br, G = SEM) como se ha definido en la segunda reivindicación que comprende:5. A procedure for the preparation of a compound of formula 1 (R = Et, X = Br, G = SEM) as has been defined in the second claim comprising: 1414
(a)(to)
Bromar el 4H,5H-tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo 3 (R = Et) para rendir el 2,7-dibromo-4H,5H-tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo 1 (R = Et, X = Br, G = H).Bromine 4 H , 5 H -thieno [3,2- b : 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate 3 (R = Et) to yield 2,7-dibromo-4 H , 5 H -thieno [3,2- b : 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate 1 (R = Et, X = Br, G = H).
15fifteen
(b)(b)
Proteger los nitrógenos del tienodipirrol 2,7-dibromo sustituido 1 (R = Et, X = Br, G = H) con cloruro de trimetilsililetoximetil para obtener el 2,7-dibromo-4H,5H-bis(trimetilsililetoximetil)tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo 1 (R = Et, X = Br, G = SEM).Protect the nitrogens of substituted 2,7-dibromo thienodipyrrole 1 (R = Et, X = Br, G = H) with trimethylsilylethoxymethyl chloride to obtain 2,7-dibromo-4 H , 5 H -bis (trimethylsilylethoxymethyl) thieno [ 3,2- b : 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate 1 (R = Et, X = Br, G = SEM).
6. Un procedimiento para la preparación de un compuesto de fórmula 1 (R = Et, X = Br, G = SEM) como se ha definido en la tercera reivindicación que consiste en proteger los nitrógenos del 2,7-dibromo-4H,5H-tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo 1 (R = Et, X = Br, G = H) con cloruro de trimetilsililetoximetil (SEM-Cl) para obtener el 2,7-dibromo-4H,5H-bis(trimetilsililetoximetil)tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo 1 (R = Et, X = Br, G = SEM).6. A process for the preparation of a compound of formula 1 (R = Et, X = Br, G = SEM) as defined in the third claim which consists of protecting the nitrogens of 2,7-dibromo-4 H , 5 H -thieno [3,2- b : 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate 1 (R = Et, X = Br, G = H) with trimethylsilylethoxymethyl chloride (SEM-Cl) to obtain 2,7-dibromo-4 H , 5 H -bis (trimethylsilylethoxymethyl) thieno [3,2- b : 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate 1 (R = Et, X = Br, G = SEM). 1616 7. Un procedimiento para la preparación de un compuesto de fórmula 1 (R = Et, X = Br, G = H) como se ha definido en la segunda reivindicación que comprende: bromar el 4H,5H-tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo 3 (R = Et) para rendir el 2,7-dibromo-4H,5H-tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo 1 (R = Et, X = Br, G = H).7. A process for the preparation of a compound of formula 1 (R = Et, X = Br, G = H) as defined in the second claim comprising: brominating 4 H , 5 H -thieno [3,2 - b : 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate 3 (R = Et) to yield 2,7-dibromo-4 H , 5 H -thieno [3,2- b : 4, 5- b ' ] diethyl dipyrrol-3,6-dicarboxylate 1 (R = Et, X = Br, G = H). 1717 8. Un procedimiento para la transformación de un compuesto de fórmula 1 (R = Et, X = Br, G = SEM) en un compuesto 9, donde R^{1} puede ser un grupo alquenilo (vinilo o estirilo), o un grupo arito el cual puede estar no sustituido o sustituido por uno o varios grupos alquilo C_{1-6}, alcoxilo C_{1-6}, hidroxi, amino, mono- o dialquilamino o hidroxicarbonilo, o un grupo heteroarilo el cual puede estar no sustituido o sustituido por uno o más grupos alquilo C_{1-6}, que comprende: someter 1 (R = Et, X = Br, G = SEM) a la reacción de Suzuki en dioxano y en presencia de un catalizador de paladio, tal como el complejo tetrakis(trifenilfosfina) paladio (0), y de una base, tal como carbonato sódico o fluoruro de cesio, con un derivado borónico 8, donde R_{2} puede ser hidrógeno (ácido borónico) o ambos R_{2} formar parte de una misma cadena hidrocarbonada (éster borónico del propilenglicol o del pinacol) para rendir el 2,7-di(R^{1})-4H,5H-bis(trimetilsililetoximetil)tieno[3,2-b:4,5-b']dipirrol-3,6-dicarboxilato de dietilo 9.8. A process for the transformation of a compound of formula 1 (R = Et, X = Br, G = SEM) into a compound 9, where R 1 can be an alkenyl group (vinyl or styryl), or a arito group which may be unsubstituted or substituted by one or more C 1-6 alkyl, C 1-6 alkoxy, hydroxy, amino, mono- or dialkylamino or hydroxycarbonyl groups, or a heteroaryl group which may be not substituted or substituted by one or more C 1-6 alkyl groups, comprising: subjecting 1 (R = Et, X = Br, G = SEM) to the reaction of Suzuki in dioxane and in the presence of a palladium catalyst , such as the tetrakis (triphenylphosphine) palladium (0) complex, and a base, such as sodium carbonate or cesium fluoride, with a boronic derivative 8, where R2 can be hydrogen (boronic acid) or both R2 2} be part of the same hydrocarbon chain (boronic ester of propylene glycol or pinacol) to yield 2,7-di (R 1) -4 H , 5 H -bis (trimethylsilylethoxymethyl) thieno [3,2- b : 4,5- b ' ] diethyl dipyrrol-3,6-dicarboxylate 9. 1818
ES200501764A 2005-07-15 2005-07-15 HALOGENATED DERIVATIVES OF 4H, 5H-TIENO (3,2-B: 4,5-B ') DIPIRROLES AND PROCEDURE AND CORRESPONDING UTILIZATIONS. Expired - Fee Related ES2275416B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200501764A ES2275416B1 (en) 2005-07-15 2005-07-15 HALOGENATED DERIVATIVES OF 4H, 5H-TIENO (3,2-B: 4,5-B ') DIPIRROLES AND PROCEDURE AND CORRESPONDING UTILIZATIONS.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200501764A ES2275416B1 (en) 2005-07-15 2005-07-15 HALOGENATED DERIVATIVES OF 4H, 5H-TIENO (3,2-B: 4,5-B ') DIPIRROLES AND PROCEDURE AND CORRESPONDING UTILIZATIONS.

Publications (2)

Publication Number Publication Date
ES2275416A1 ES2275416A1 (en) 2007-06-01
ES2275416B1 true ES2275416B1 (en) 2008-06-01

Family

ID=38328812

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200501764A Expired - Fee Related ES2275416B1 (en) 2005-07-15 2005-07-15 HALOGENATED DERIVATIVES OF 4H, 5H-TIENO (3,2-B: 4,5-B ') DIPIRROLES AND PROCEDURE AND CORRESPONDING UTILIZATIONS.

Country Status (1)

Country Link
ES (1) ES2275416B1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01172387A (en) * 1987-12-25 1989-07-07 Sumitomo Chem Co Ltd Dipyrrolo(3,2-b:2',3'-d)pyrroles and production thereof
CA2448570A1 (en) * 2001-05-31 2002-12-05 Miravant Pharmaceuticals, Inc. Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis
ES2197818B1 (en) * 2002-06-11 2005-02-01 Institut Quimic De Sarria Cets 2,7,12,17 ALQUENIL, ARIL AND HETEROARIL DERIVED FROM 3,6,13,16-TETRAAZAPORFICENO, AND PROCEDURE, INTERMEDIATE COMPOUND AND CORRESPONDING UTILIZATIONS.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NONELL, S. et al. "Synthesis of 2,7,12,17-Tetraphenylporphycene (TPPo). First Aryl-Substituted Porphycene for the Photodynamic Therapy or Tumors". Tetrahedron Letters, 1995, Volumen 36, Número 19, páginas 3405-3408. *

Also Published As

Publication number Publication date
ES2275416A1 (en) 2007-06-01

Similar Documents

Publication Publication Date Title
Zheng et al. Synthesis, photophysical properties, tumor uptake, and preliminary in vivo photosensitizing efficacy of a homologous series of 3-(1 ‘-alkyloxy) ethyl-3-devinylpurpurin-18-N-alkylimides with variable lipophilicity
Bonnett et al. Photophysical properties of meso‐tetraphenylporphyrin and some meso‐tetra (hydroxyphenyl) porphyrins
Awuah et al. Boron dipyrromethene (BODIPY)-based photosensitizers for photodynamic therapy
AU664377B2 (en) Porphycene compounds for photodynamic therapy
CN101102766B (en) Novel derivatives of porphyrin, particularly chlorins and/orbacteriochlorins, and uses thereof in photodynamic therapy
US5409900A (en) Porphycene compounds for photodynamic therapy
CA2335514C (en) Alkyl ether analogs of chlorins having an n-substituted imide ring
Bonnett et al. Photobleaching of compounds of the 5, 10, 15, 20-Tetrakis (m-hydroxyphenyl) porphyrin Series (m-THPP, m-THPC, and m-THPBC)
US6462192B2 (en) Processes for large scale production of tetrapyrroles
Pandey et al. Syntheses of water-soluble cationic porphyrins and chlorins
WO2003104237A1 (en) 2,7,12,17 alkenyl, aryl and heteroaryl derived from 3,6,13,16-tetraazaporphycene, method, intermediate compound and corresponding utilizations
Reshetnickov et al. Novel drug form of chlorin e6
ES2275416B1 (en) HALOGENATED DERIVATIVES OF 4H, 5H-TIENO (3,2-B: 4,5-B ') DIPIRROLES AND PROCEDURE AND CORRESPONDING UTILIZATIONS.
Gorman et al. An overview of synthetic approaches to porphyrin, phthalocyanine, and phenothiazine photosensitizers for photodynamic therapy
CA2462508A1 (en) Photosensitizing carbamate derivatives
ES2333006T3 (en) TETRAPIRROLIC MACROCICLES AS PHOTODYNAMIC AGENTS.
CA2399217A1 (en) Porphyrins and related compounds
JP4866854B2 (en) Boronated metal phthalocyanine, process for its preparation, pharmaceutical composition having the same and use thereof
ES2319008B1 (en) USE OF PERFORMANCE DERIVATIVES IN PHOTODYNAMIC BIFOTONIC THERAPY.
Ghogare et al. Synthesis of a poly (ethylene glycol) galloyl sensitizer tip for an’all‐in‐one'photodynamic device
Masuno et al. A new porphycene-derived ring structure: octaethylbenzochloracene
KR100396342B1 (en) Rubyrin derivatives, a preparing method thereof and there use
WO2000044742A1 (en) Improved sensitizers for use in photodynamic therapy
Winter et al. Efficient Far-Red/Near-IR Absorbing BODIPY Photocages by Blocking Unproductive Conical Intersections
Pandey et al. Improved photosensitizers for photodynamic therapy

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20070601

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2275416B1

Country of ref document: ES

FD1A Patent lapsed

Effective date: 20100315